Sector: HealthcareIndustry: Biotechnology

Arbutus Biopharma Corp

NASDAQ: ABUS•https://www.arbutusbio.com

Current Price

Analyst Sentiment

4 ratings: Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to developing innovative therapies for chronic hepatitis B virus (HBV) infection, with its headquarters located in Warminster, Pennsylvania. Utilizin...|

Overview

Market Cap$801.99M

52W High / Low$5 / $3

P/EN/A

PEG0.00

Book Value$0.40

Dividend/ShareN/A

Dividend YieldN/A

EPS$-0.23

Revenue/Share$0.08

OPM-15.68%

NPM-2.89%

ROA-16.50%

ROE-45.90%

Gross Profit$-14.44M

Forward PEN/A

Price to Sales54.91

Price to Book10.46

EV to Sales49.08

EV to EBITDA-5.64

Beta0.65

50D Moving Avg$4.44

200D Moving Avg$3.68

Institutional Holding62.59%

Insider Holding21.80%

Trailing P/EN/A

Qtr EPS GrowthN/A

Qtr Revenue Growth-60.50%

Add ratio to table

e.g. Promoter holding

Edit Ratios

Loading price data...

Earnings Estimates

Analyst consensus EPS and Revenue forecasts.

Show growth under values

Years:

Unit:

Metric (B)	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
EPS Estimate (avg)	$-0.86	$-0.45	$-0.45	$-0.55	$-0.26	$-0.23
Revenue Estimate (avg)	0.01	0.04	0.02	0.01	0.02	0
EPS Revision (30d avg)	+0.0%	+0.0%	+0.0%	-0.9%	-2.4%	+9.2%

Peer Comparison

Showing 5 peers (Same Industry)

S.No.	Name	Symbol	Market Cap	P/E	P/B	Profit Margin	Op. Margin	ROE	Rev. Growth
1.	Ginkgo Bioworks Holdings Inc - Class A	DNA	$520.47M	—	0.94	-188.00%	-227.30%	-50.00%	-56.40%
2.	Entrada Therapeutics Inc	TRDA	$376.46M	—	1.11	-168.20%	-2,915.00%	-27.10%	-91.80%
3.	Immatics N.V	IMTX	$1.20B	—	2.69	-141.60%	-1,053.00%	-30.00%	-89.70%
4.	Ascentage Pharma Group International	AAPG	$3.03B	—	32.10	-296.80%	-237.00%	-159.70%	-71.60%
5.	Silence Therapeutics Plc	SLN	$326.86M	—	4.30	-249.90%	-14,881.00%	-64.30%	-89.40%

Quarterly Results

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Quarters:

Unit:

Quarter (M)	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25
Sales	2.15	1.53	1.73	1.34	1.57	1.76	10.74	0.53
Expenses	5.33	20.89	23.31	22.78	6.7	27.46	9.25	8.81
Operating Profit	-20.52	-17.83	-19.76	-19.69	-15.67	-24.5	2.55	-7.72
OPM %	-954.42%	-1165.36%	-1142.2%	-1469.4%	-998.09%	-1392.05%	23.74%	-1456.6%
Other Income	0	0	0	0	0	0	0	0
Interest	1.42	1.5	1.79	1.72	1.43	1.17	1.01	0.93
Depreciation	0.36	0.35	0.36	0.34	0.33	0.33	0.01	0.01
Profit Before Tax	-19.31	-17.88	-19.8	-19.72	-12.53	-24.53	2.52	-7.74
Tax %	-5.54%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-19.31	-17.88	-19.8	-19.72	-12.53	-24.53	2.52	-7.74
EPS	0	0	0	0	0	0	0	0

Profit & Loss

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales	24.87	1.5	10.7	5.9	6.01	6.91	10.99	39.02	18.14	6.17
COGS	51.51	61.3	62.7	57.9	57.6	47.48	1.75	1.43	73.7	1.38
Gross Profit	-26.63	-59.8	-52	-52	-51.59	-40.57	10.99	39.02	18.14	6.17
Gross Profit %	-107.08%	-3986.67%	-485.98%	-881.36%	-858.4%	-587.12%	100%	100%	100%	100%
Operating Exp	78.53	101.8	80.8	76.1	92.31	17.24	84.51	104.47	96.24	82.49
EBITDA	-76.72	-488.07	-106.44	-58.95	-162.24	-57.76	-71.64	-61.86	-70.99	-68.4
Other Income	25.02	2.47	2.46	28.66	24.85	-1.93	0.13	2.17	0	0
Interest	25.11	0	1.28	2.85	0	-3.27	-2.73	0.47	4.71	6.45
Depreciation	0.59	1.09	2.03	2.18	2.03	1.98	1.75	1.43	1.4	1.38
Profit Before Tax	-77.31	-489.1	-108.7	-61.4	-166.38	-63.74	-76.25	-65.01	-72.85	-69.92
Tax Rate %	20.93%	21.47%	22.36%	7%	7.61%	-2.31%	-1.44%	-6.83%	0%	0%
Net Profit	-61.12	-384.1	-84.4	-57.1	-153.72	-63.74	-76.25	-69.46	-72.85	-69.92

Balance Sheet

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash & Bank	166.78	23.4	54.3	36.94	31.8	52.25	109.28	30.78	26.29	36.33
Investments	24.59	107.1	72.1	109.9	59.03	71.02	81.72	153.5	106	86.29
Fixed Assets	3.18	6.95	12.18	10.14	8.68	6.93	5.98	5.07	0	0
Current Assets	3.65	2.1	3	4.61	2.99	1.31	0.9	1.35	4.25	4.69
Other Assets	514.09	136.35	95.62	66.31	3.03	5.57	6.6	4.72	7.87	4.39
Total Assets	712.29	275.9	237.2	227.91	105.53	137.08	204.49	195.42	144.4	131.71
Equity Capital	834.24	867.39	876.11	879.4	898.53	985.94	1,286.64	1,318.74	1,349.82	1,410.03
Reserves	-286.56	-664.39	-693.61	-679.17	-825.79	-883.97	-1,117.2	-1,181.88	-1,243.8	-1,312.66
Borrowing/Debt	6.22	18.67	17.97	0	3.36	22.54	18.91	12.55	8.72	1.29
Current Liabilities	9.71	3.92	3.19	11.24	7.49	9.15	10.84	16.03	10.27	7.56
Other Liabilities	148.69	50.31	33.54	16.43	21.95	3.43	5.3	29.99	19.39	25.49
Total Liabilities & Equity	712.29	275.9	237.2	227.91	105.53	137.08	204.49	195.42	144.4	131.71

Cash Flow Statement

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash Flow from Operating	-54.78	-57.88	-48.6	-67.9	-71.01	-51.44	-67.53	-35.36	-85.94	-64.85
Cash Flow from Investing	7.68	-99.12	27.8	-4.1	28.34	-14.91	-12.68	-74.94	50.77	22.95
Cash Flow from Financing	143.87	12.64	49.3	55.6	37.46	86.75	137.24	31.81	30.65	52
Net Cash Flow	94.59	-143.37	30.88	-17.35	-5.14	20.4	57.03	-78.48	0	0